Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy

Ruzek, Lukas; Konečný, Tomáš; Souček, Filip; Konecny, Dana; Mach, Lukáš; Ommen, Steve R.; Kopecky, Stephen L.; Nishimura, Rick A.

doi:10.1016/j.amjcard.2015.05.022

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with LVOTO and concomitant disease requiring pharmacological treatment, caution is required with vasodilators and/or positive inotropic agents, because of the risk of exacerbation of LVOTO; examples include phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction, methamphetamine for attention deficit hyperactivity disorder, angiotensin‐converting enzyme inhibitors (ACEi), or angiotensin receptor blockers (ARBs) for treatment of concomitant systemic hypertension. Nevertheless, these drugs often seem well tolerated …”

Section: Treatment Of Dynamic Left Ventricular Outflow Tract Obstructionmentioning

confidence: 99%

“…Nevertheless, these drugs often seem well tolerated. 9,34,35 In the presence of asymptomatic patients with high resting or provokable gradients, one should always question the true lack of symptoms vs. lifestyle adaptation. These patients often have demonstrable exercise limitation, which is exacerbated by meals.…”

Section: Dynamic Left Ventricular Outflow Tract Obstructionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives

Ammirati

Contri

Coppini

et al. 2016

European J of Heart Fail

106

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is entering a phase of intense translational research that holds promise for major advances in disease-specific pharmacological therapy. For over 50 years, however, HCM has largely remained an orphan disease, and patients are still treated with old drugs developed for other conditions. While judicious use of the available armamentarium may control the clinical manifestations of HCM in most patients, specific experience is required in challenging situations, including deciding when not to treat. The present review revisits the time-honoured therapies available for HCM, in a practical perspective reflecting real-world scenarios. Specific agents are presented with doses, titration strategies, pros and cons. Peculiar HCM dilemmas such as treatment of dynamic outflow obstruction, heart failure caused by end-stage progression and prevention of atrial fibrillation and ventricular arrhythmias are assessed. In the near future, the field of HCM drug therapy will rapidly expand, based on ongoing efforts. Approaches such as myocardial metabolic modulation, late sodium current inhibition and allosteric myosin inhibition have moved from pre-clinical to clinical research, and reflect a surge of scientific as well as economic interest by academia and industry alike. These exciting developments, and their implications for future research, are discussed.

show abstract

Section: Treatment Of Dynamic Left Ventricular Outflow Tract Obstructionmentioning

confidence: 99%

Section: Dynamic Left Ventricular Outflow Tract Obstructionmentioning

confidence: 99%

Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives

Ammirati

Contri

Coppini

et al. 2016

European J of Heart Fail

106

View full text Add to dashboard Cite

show abstract

“…3 In the past 10 years, the connection between SDB and HCM has been under increasing investigation, and this effort has identified association between untreated SDB and several adverse characteristics relevant to HCM: worse functional New York Heart Association class, 4 worse peak exercise oxygen consumption, 5 more frequent atrial fibrillation and enlarged left atrial size (potent predictors of survival in HCM), 6,7 and increased mean heart rate (target of b-blocker therapy, the up-titration of which can be limited by side-effects in HCM). 8,9 In this editorial we will attempt to coalesce the evolving framework of SDB-HCM interaction with the findings from the informative manuscript by Cui et al 10 published in this issue of Mayo Clinic Proceedings. 10 The esteemed authors of this novel study reviewed HCM patients who underwent clinically indicated septal myectomy at a specialized HCM center of excellence.…”

mentioning

confidence: 99%